- Home
- GOW vs ANIX Comparison
GOW vs ANIX Comparison
Compare GOW & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOW | ANIX |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil and Gas Field Machinery | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 114.0M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GOW | ANIX |
|---|---|---|
| Price | $3.40 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 727.3K | 218.1K |
| Earning Date | 10-21-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $2.32 |
| 52 Week High | $4.92 | $5.46 |
Technical Indicators
Market Signals| Indicator | GOW | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 57.76 |
| Support Level | $3.02 | $2.82 |
| Resistance Level | $4.57 | $3.09 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 24.52 | 75.93 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.